[go: up one dir, main page]

WO2010139979A3 - Processes for preparing crystalline forms of dasatinib - Google Patents

Processes for preparing crystalline forms of dasatinib Download PDF

Info

Publication number
WO2010139979A3
WO2010139979A3 PCT/GB2010/050892 GB2010050892W WO2010139979A3 WO 2010139979 A3 WO2010139979 A3 WO 2010139979A3 GB 2010050892 W GB2010050892 W GB 2010050892W WO 2010139979 A3 WO2010139979 A3 WO 2010139979A3
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
processes
crystalline forms
preparing crystalline
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/050892
Other languages
French (fr)
Other versions
WO2010139979A2 (en
Inventor
Vinayak Govind Gore
Laxmikant Patkar
Amit Bagul
Priyesh Surendra Vijaykar
Mahesh Edake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Mylan Pharmaceuticals Pvt Ltd
Original Assignee
Generics UK Ltd
Mylan India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd, Mylan India Pvt Ltd filed Critical Generics UK Ltd
Publication of WO2010139979A2 publication Critical patent/WO2010139979A2/en
Publication of WO2010139979A3 publication Critical patent/WO2010139979A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to intermediates and their preparation, for use in the manufacture of pure dasatinib, in particularly dasatinib monohydrate and anhydrous dasatinib. The invention also relates to pharmaceutical compositions comprising pure dasatinib and their use in the treatment of cancer.
PCT/GB2010/050892 2009-06-03 2010-05-28 Processes for preparing crystalline forms Ceased WO2010139979A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN829KO2009 2009-06-03
IN829/KOL/2009 2009-06-03
IN828KO2009 2009-06-03
IN828/KOL/2009 2009-06-03

Publications (2)

Publication Number Publication Date
WO2010139979A2 WO2010139979A2 (en) 2010-12-09
WO2010139979A3 true WO2010139979A3 (en) 2011-05-05

Family

ID=42734619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050892 Ceased WO2010139979A2 (en) 2009-06-03 2010-05-28 Processes for preparing crystalline forms

Country Status (1)

Country Link
WO (1) WO2010139979A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891738B (en) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 Dasatinib polymorph, its preparation method and pharmaceutical composition
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 New polymorphic form of dasatinib and preparation method thereof
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
CN102408423B (en) * 2011-11-29 2013-12-25 上海希迪制药有限公司 Method for preparing large particle size dasatinib
WO2013078973A1 (en) * 2011-11-29 2013-06-06 上海创诺制药有限公司 Large particle diameter dasatinib and preparation and use thereof
NZ630288A (en) * 2012-04-20 2015-08-28 Shilpa Medicare Ltd Process for preparing dasatinib monohydrate
CN103709156B (en) * 2012-09-29 2016-08-03 石药集团中奇制药技术（石家庄）有限公司 A kind of Dasatinib polycrystalline form medicament and preparation method thereof
CZ306598B6 (en) * 2012-12-06 2017-03-22 Zentiva, K.S. A method of preparation and purification of new and known polymorphs and dasatinib solvates
CN103408542B (en) * 2013-08-13 2016-06-29 南京优科生物医药研究有限公司 A kind of preparation method of highly purified Dasatinib anhydride
IN2013MU03610A (en) * 2013-12-18 2015-04-24 Dharmesh Mahendrabhai Shah
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
US10800771B2 (en) 2016-12-01 2020-10-13 Natco Pharma Limited Process for the preparation of dasatinib polymorph
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
CN115192540A (en) 2018-06-15 2022-10-18 汉达癌症医药责任有限公司 Salts of kinase inhibitors and compositions thereof
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) * 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937270A1 (en) 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) * 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Also Published As

Publication number Publication date
WO2010139979A2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
WO2010092090A3 (en) Novel salts of sitagliptin
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
IL214396A (en) Carba-nucleosides for antiviral treatment, pharmaceutical compositions comprising the same and methods of making carba-nucleosides and intermediates of carba-nucleosides for antiviral treatment
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011130615A3 (en) Preparation of lacosamide
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
IN2012DN03182A (en)
EP2431366A4 (en) New chlorine e6-folic acid conjugated compound, preparation method thereof, and pharmaceutical composition containing the same for treatment of cancer
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
PL2429507T3 (en) Phosphate-free pharmaceutical composition for the treatment of glaucoma
WO2011006935A3 (en) Tetrazole derivatives
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
MX2012001691A (en) Orally disintegrating compositions of linaclotide.
IN2013DN02555A (en)
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2011069032A3 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
WO2010131035A8 (en) Novel crystalline polymorph of sitagliptin dihydrogen phosphate
WO2010061220A3 (en) Novel processes and pure polymorphs
WO2011027359A3 (en) Process for the preparation of 4 -hydroxy atomoxetine and intermediates in the manufacture thereof
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
WO2010146595A3 (en) Novel polymorphs of flibanserin hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722771

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10722771

Country of ref document: EP

Kind code of ref document: A2